Analysis of responder-based endpoints: improving power through utilising continuous components
Open accessPublished version of a preprint
The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
Background: Clinical trials and other studies commonly assess the effectiveness of an intervention through the use of responder-based endpoints. These classify patients based on whether they meet a number of criteria which often involve continuous variables categorised as being above or below a threshold. The proportion of patients who are responders is estimated and, where relevant, compared between groups. An alternative method called the augmented binary method keeps the definition of the endpoint the same but utilises information contained within the continuous component to increase the power considerably (equivalent to increasing the sample size by > 30%). In this article we summarise the method and investigate the variety of clinical conditions that use endpoints to which it could be applied. Methods: We reviewed a database of core outcome sets (COSs) that covered physiological and mortality trial endpoints recommended for collection in clinical trials of different disorders. We identified responder-based endpoints where the augmented binary method would be useful for increasing power. Results: Out of the 287 COSs reviewed, we identified 67 new clinical areas where endpoints were used that would be more efficiently analysed using the augmented binary method. Clinical areas that had particularly high numbers were rheumatology (11 clinical disorders identified), non-solid tumour oncology (10 identified), neurology (9 identified) and cardiovascular (8 identified). Conclusions: The augmented binary method can potentially provide large benefits in a vast array of clinical areas. Further methodological development is needed to account for some types of endpoints.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using this method substantially reduces the sample size needed for a power of 90%.”
From Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This trial represents the first time that the augmented binary method25 has been used prospectively to set the power of the trial at 90% while reducing the sample size required for this level of power.”
The cited source says what the claim attributes to it.
In the citing paper
“For the analysis of the primary outcome, we will use the augmented binary method.25”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Analysis of Transformations
Box, G. E. P., & Cox, D. R. (1964) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1964.tb00553.x · Cited by 15,052 · cited 1×
“This means that it is necessary to check this prior to analysing the data and use a suitable correction if assumptions are not met, such as applying a Box-Cox transformation [15] to ensure that the continuous component is normally distributed.”
MethodThe cost of dichotomising continuous variables
Altman, D. G., & Royston, P. (2006) · BMJ · doi:10.1136/bmj.332.7549.1080 · Cited by 2,688
Core Outcome Set-STAndards for Development: The COS-STAD recommendations
Kirkham, J. J., Davis, K., Altman, D. G., Blazeby, J. M., Clarke, M., Tunis, S., & Williamson, P. R. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002447 · Cited by 792
A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery
Dodd, S., Clarke, M., Becker, L., Mavergames, C., Fish, R., & Williamson, P. R. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.12.020 · Cited by 625
Self-citationA conceptual and empirical examination of justifications for dichotomization.
DeCoster, J., Iselin, A.-M. R., & Gallucci, M. (2009) · Psychological Methods · doi:10.1037/a0016956 · Cited by 482
Choosing Important Health Outcomes for Comparative Effectiveness Research: A Systematic Review
Gargon, E., Gurung, B., Medley, N., Altman, D. G., Blazeby, J. M., Clarke, M., & Williamson, P. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099111 · Cited by 337
Analysis of data with excess zeros
Lachenbruch, P. A. (2002) · Statistical Methods in Medical Research · doi:10.1191/0962280202sm289ra · Cited by 148
Gargon, E., Gorst, S. L., & Williamson, P. R. (2019) · PLOS ONE · doi:10.1371/journal.pone.0225980 · Cited by 143
Gargon, E., Gorst, S. L., Harman, N. L., Smith, V., Matvienko-Sikar, K., & Williamson, P. R. (2018) · PLOS ONE · doi:10.1371/journal.pone.0209869 · Cited by 111
Weinblatt, M. E., Genovese, M. C., Ho, M., Hollis, S., Jedrychowicz‐Rosiak, K., Kavanaugh, A., Millson, D. S., León, G., Wang, M., & van der Heijde, D. M. F. M. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38851 · Cited by 109
Cited by
NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure
Schmitt, W., Ruehs, H., Burghaus, R., Diedrich, C., Duwal, S., Eißing, T., Garmann, D., Meyer, M. C., Ploeger, B. A., & Lippert, J. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2222 · Cited by 53
Grayling, M. J., Bigirumurame, T., Cherlin, S., Ouma, L. O., Zheng, H., & Wason, J. M. S. (2021) · BMC Rheumatology · doi:10.1186/s41927-021-00192-5 · Cited by 27
Self-citationPridopidine in early-stage manifest Huntington’s disease: a phase 3 trial
Reilmann, R., Feigin, A., Rosser, A., Kostyk, S. K., Carsten Saft, C., Cohen, Y. C., Schuring, H., Hand, R., Tan, A. M., Chen, K. S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03920-3 · Cited by 25
“However, despite the advantages of performing a responder analysis 37,63,64 , choosing a single specific cutoff to define a responder can be a limitation.”
Improving the analysis of composite endpoints in rare disease trials
McMenamin, M. E., Berglind, A., & Wason, J. M. S. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0819-1 · Cited by 18
Self-citationResearchers in rheumatology should avoid categorization of continuous predictor variables
Salis, Z., Gallego, B., & Sainsbury, A. (2023) · BMC Medical Research Methodology · doi:10.1186/s12874-023-01926-4 · Cited by 15
Metadata
- Authors
- Wason, J., McMenamin, M., & Dodd, S.
- Affiliations
- University of Cambridge (GB)
- University of Liverpool (GB)
- Corresponding author
- Wason, James
- Venue
- Trials
- Published
- 2020-05-25
- Volume
- 21
- Issue
- 1
- Pages
- 427-427
- ISSN
- 1745-6215 (ISSN-L)
- PMC
- PMC7249409
- OpenAlex
- W3032450192
- Cited by
- 16
- References
- 25
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 5
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Trials (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Apollo (cc-by)
- Apollo
- Funders
- Medical Research Council (MC_UU_00002/6)
- Cancer Research UK (C48553/A1811)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Keywords
- statistical power, core outcome set, clinical trial endpoints, threshold-based classification, sample size, rheumatology, neurology, cardiovascular clinical trials
- MeSH terms
- Clinical Trials as Topic, Data Interpretation, Statistical, Humans, Outcome Assessment, Health Care, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Analysis of responder-based endpoints: improving power through utilising continuous components. https://app.cochat.ai/papers/10.1186/s13063-020-04353-8
- The paper
- Wason, J., McMenamin, M., & Dodd, S. (2020). Analysis of responder-based endpoints: improving power through utilising continuous components. Trials. https://doi.org/10.1186/s13063-020-04353-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.